Harvard Bioscience Inc (HBIO) stock
Close on Nov 17, 2026Market cap $41.33MP/E –Yield –
Earnings
Harvard Bioscience's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Harvard Bioscience's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 11, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 10, 2026before the open | $22.20M | +7.8% | -$0.58 | -$0.06 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 11, 2026before the open | $22.70M | +10.7% | -$0.64 | -$0.14 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 12, 2026before the open | $20.80M | -4.6% | -$0.77 | -$0.33 | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 12, 2026before the open | $23.70M | -3.7% | -$0.06 | $0.00 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $20.60M | -6.4% | -$0.03 | $0.00 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 11, 2025before the open | $20.50M | -11.3% | -$0.05 | -$0.01 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025before the open | $21.80M | -11.0% | -$1.14 | -$0.01 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 12, 2025before the open | $24.60M | -12.8% | $0.00 | $0.06 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 7, 2024before the open | $22.00M | -13.4% | -$0.11 | -$0.02 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024before the open | $23.10M | -19.8% | -$0.07 | $0.00 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | $24.50M | -18.3% | -$0.11 | $0.02 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024before the open | $28.20M | -0.7% | -$0.04 | $0.04 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $25.40M | -5.6% | -$0.03 | $0.01 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $28.80M | -1.4% | -$0.02 | $0.04 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 25, 2023before the open | $30.00M | +4.2% | $0.01 | $0.06 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023before the open | $28.40M | -14.2% | -$0.04 | $0.04 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022during market hours | $26.90M | -9.4% | -$0.08 | -$0.01 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022before the open | $29.20M | – | $0.06 | $0.05 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 4, 2022before the open | $28.80M | – | -$0.17 | $0.04 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 8, 2022before the open | $33.10M | – | $0.02 | $0.08 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 3, 2021before the open | $29.70M | – | $0.00 | $0.06 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 10, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Harvard Bioscience's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| RevenueGAAP | Q4 FY2026 | $23.70M – $25.50M | – | New | Nov 10, 2026 |
| Adjusted gross marginnon-GAAP | Q4 FY2026 | 59% – 61% | – | New | Nov 10, 2026 |
| Adjusted EBITDAnon-GAAP | Q4 FY2026 | $3.80M – $4.20M | – | New | Nov 10, 2026 |
| Revenue growthGAAP | FY2026 | +3% – +5% | – | New | Nov 10, 2026 |
| Revenue growth | FY2026 | +3% – +5% | +2% – +4% | Raised | Aug 11, 2026 |
| Revenue growth | FY2026 | +2% – +4% | – | New | Mar 12, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | 57% – 59% | 58% – 60% | Lowered | Nov 10, 2026 |
| Adjusted gross marginnon-GAAP | FY2026 | 57% – 59% | 58% – 60% | Lowered | Aug 11, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | -1% – +4% | +6% – +10% | Lowered | Nov 10, 2026 |
| Adjusted EBITDA growthnon-GAAP | FY2026 | +6% – +10% | +6% – +10% | Reaffirmed | Aug 11, 2026 |
Guidance vs results
The last range Harvard Bioscience gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q3 FY2026 | Revenue | $21.00M – $22.60M | $22.20M | Within range |
| Q2 FY2026 | Revenue | $20.50M – $22.50M | $22.70M | Above range |
| Q1 FY2026 | Revenue | $20.00M – $22.00M | $20.80M | Within range |
| Q4 FY2025 | Revenue | $22.50M – $24.50M | $23.70M | Within range |
| Q3 FY2025 | Revenue | $19.00M – $21.00M | $20.60M | Within range |
| Q2 FY2025 | Revenue | $18.00M – $20.00M | $20.50M | Above range |
| Q1 FY2025 | Revenue | $19.00M – $21.00M | $21.80M | Above range |
| Q4 FY2024 | Revenue | $23.00M – $26.00M | $24.60M | Within range |
| Q4 FY2022 | Revenue | $30.00M | $28.40M | Below range |
Guidance history
Every forecast Harvard Bioscience put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2026 | Adjusted EBITDA | Q4 FY2026 | $3.80M – $4.20M | New |
| Nov 10, 2026 | Adjusted EBITDA | FY2026 | -1% – +4% | Lowered |
| Nov 10, 2026 | Adjusted gross margin | Q4 FY2026 | 59% – 61% | New |
| Nov 10, 2026 | Adjusted gross margin | FY2026 | 57% – 59% | Lowered |
| Nov 10, 2026 | Revenue | Q4 FY2026 | $23.70M – $25.50M | New |
| Nov 10, 2026 | Revenue growth | FY2026 | +3% – +5% | New |
| Aug 11, 2026 | Adjusted EBITDA growth | FY2026 | +6% – +10% | Reaffirmed |
| Aug 11, 2026 | Adjusted EBITDA | Q3 FY2026 | $1.50M – $2.50M | New |
| Aug 11, 2026 | Adjusted gross margin | FY2026 | 57% – 59% | Lowered |
| Aug 11, 2026 | Adjusted gross margin | Q3 FY2026 | 56% – 58% | New |
| Aug 11, 2026 | Revenue growth | FY2026 | +3% – +5% | Raised |
| Aug 11, 2026 | Revenue | Q3 FY2026 | $21.00M – $22.60M | New |
| May 12, 2026 | Adjusted EBITDA growth | FY2026 | +6% – +10% | New |
| May 12, 2026 | Adjusted EBITDA | Q2 FY2026 | $1.00M – $2.00M | New |
| May 12, 2026 | Adjusted gross margin | FY2026 | 58% – 60% | New |
| May 12, 2026 | Adjusted gross margin | Q2 FY2026 | 57% – 59% | New |
| May 12, 2026 | Revenue growth | FY2026 | +2% – +4% | New |
| May 12, 2026 | Revenue | Q2 FY2026 | $20.50M – $22.50M | New |
| Mar 12, 2026 | Adjusted EBITDA | Q1 FY2026 | $1.00M – $2.20M | New |
| Mar 12, 2026 | Adjusted EBITDA growth | FY2026 | +6% – +10% | New |
| Mar 12, 2026 | Adjusted gross margin | Q1 FY2026 | 57% – 59% | New |
| Mar 12, 2026 | Adjusted gross margin | FY2026 | 58% – 60% | New |
| Mar 12, 2026 | Revenue | Q1 FY2026 | $20.00M – $22.00M | New |
| Mar 12, 2026 | Revenue growth | FY2026 | +2% – +4% | New |
| Nov 6, 2025 | gross margin | Q4 FY2025 | 58% – 60% | New |
| Nov 6, 2025 | revenues | Q4 FY2025 | $22.50M – $24.50M | New |
| Aug 11, 2025 | gross margin | Q3 FY2025 | 56% – 58% | New |
| Aug 11, 2025 | revenues | Q3 FY2025 | $19.00M – $21.00M | New |
| May 12, 2025 | gross margin | Q2 FY2025 | 55% – 57% | New |
| May 12, 2025 | revenues | Q2 FY2025 | $18.00M – $20.00M | New |
| Mar 12, 2025 | gross margin | Q1 FY2025 | 56% – 58% | New |
| Mar 12, 2025 | revenues | Q1 FY2025 | $19.00M – $21.00M | New |
| Nov 7, 2024 | gross margins | Q4 FY2024 | 59% – 60% | New |
| Nov 7, 2024 | revenues | Q4 FY2024 | $23.00M – $26.00M | New |
| Aug 8, 2024 | gross margin | FY2024 | 59% – 60% | Lowered |
| Aug 8, 2024 | revenue outlook | FY2024 | $97.00M – $102.00M | New |
| May 7, 2024 | gross margin | FY2024 | 60% | New |
| Mar 7, 2024 | gross margin | FY2024 | 60% | New |
| Nov 7, 2023 | adjusted EBITDA margins | FY2023 | 13% – 14% | Lowered |
| Nov 7, 2023 | gross margins | FY2023 | 60% | New |
| Nov 7, 2023 | net leverage ratio | FY2023 | 2 | Reaffirmed |
| Aug 8, 2023 | adjusted EBITDA margins | FY2023 | 15% – 17% | Lowered |
| Aug 8, 2023 | gross margins | FY2023 | 60% | Reaffirmed |
| Aug 8, 2023 | net leverage ratio | FY2023 | 2 | New |
| Aug 8, 2023 | revenues | FY2023 | $116.00M – $120.00M | New |
| Apr 25, 2023 | adjusted EBITDA margins | FY2023 | 16% – 17% | New |
| Apr 25, 2023 | gross margins | FY2023 | 60% | New |
| Nov 8, 2022 | adjusted operating margin | Q4 FY2022 | 14% – 15% | New |
| Nov 8, 2022 | revenue | Q4 FY2022 | $30.00M | New |
| Aug 4, 2022 | adjusted operating margin | FY2022 | 13% – 14% | Lowered |
| Aug 4, 2022 | reported revenue growth | FY2022 | +1% – +5% | Lowered |
| May 4, 2022 | adjusted operating margins | FY2022 | 14% – 16% | Lowered |
| May 4, 2022 | annual revenue growth guidance | FY2022 | +8% – +13% | New |
| Mar 8, 2022 | adjusted operating margins | FY2022 | 15% – 16% | New |
| Mar 8, 2022 | reported revenue growth | FY2022 | +10% – +13% | New |
| Nov 3, 2021 | revenue growth | FY2021 | +15% – +17% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Harvard Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Update
- Update
- Results
- Update
- Results
See a number that looks wrong?